drug therapy

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
Mohamed A Ghonim, Salome V Ibba, Abdelmetalab F Tarhuni, Youssef Errami, Hanh H Luu, Matthew J Dean, Ali H El-Bahrawy, Dorota Wyczechowska, Ilyes A Benslimane, Luis Del Valle, Amir A Al-Khami, Augusto C Ochoa, A Hamid Boulares

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001643; DOI: 10.1136/jitc-2020-001643
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Chao Liu, Ruiqi Liu, Bojun Wang, Jie Lian, Yang Yao, Haoxiu Sun, Chunhui Zhang, Lin Fang, Xin Guan, Jiaqi Shi, Shuling Han, Fei Zhan, Shengnan Luo, Yuanfei Yao, Tongsen Zheng, Yanqiao Zhang

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001895; DOI: 10.1136/jitc-2020-001895
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, Barbara A Goff

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003122; DOI: 10.1136/jitc-2021-003122
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Leyre Zubiri, Gabriel E Molina, Meghan J Mooradian, Justine Cohen, Sienna M Durbin, Laura Petrillo, Genevieve M Boland, Dejan Juric, Michael Dougan, Molly F Thomas, Alex T Faje, Michelle Rengarajan, Amanda C Guidon, Steven T Chen, Daniel Okin, Benjamin D Medoff, Mazen Nasrallah, Minna J Kohler, Sara R Schoenfeld, Rebecca K Leaf, Meghan E Sise, Tomas G Neilan, Daniel A Zlotoff, Jocelyn R Farmer, Aditya Bardia, Ryan J Sullivan, Steven M Blum, Yevgeniy R Semenov, Alexandra-Chloé Villani, Kerry L Reynolds

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e002886; DOI: 10.1136/jitc-2021-002886
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Siming Li, Xiaowen Wu, Xieqiao Yan, Li Zhou, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Jie Dai, Yan Kong, Xiongwen Tang, Hui Feng, Sheng Yao, Keith T Flaherty, Jun Guo, Xinan Sheng

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e004036; DOI: 10.1136/jitc-2021-004036
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J George, Thomas Hutson, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003844; DOI: 10.1136/jitc-2021-003844
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak, David S Hong

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003776; DOI: 10.1136/jitc-2021-003776
Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
Jianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie Liang, Yanli Guo, Juanjuan Ou

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003408; DOI: 10.1136/jitc-2021-003408
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J Backes, Theresa L Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S Ohashi, David G Brooks, Gini F Fleming

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004233; DOI: 10.1136/jitc-2021-004233
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lépine, Johann de Bono

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003697; DOI: 10.1136/jitc-2021-003697

Main menu

drug therapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

drug therapy

Pages